4篇
您的检索式：作者名="Provencher S."
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | β-受体阻断剂对门肺高压患者运动能力及血流动力学的不良影响显示文摘Background &Aims: It has been suggested that β-blockers might be harmful in pulmonary arterial hypertension. However, no study has evaluated the effect of β-blockers in these patients. The aim of this study was to investigate the effect of β-blockers on exercise capacity and pulmonary hemodynamics in patients with portopulmonary hypertension receiving β-blockers for the prophylaxis of variceal bleeding. Methods: Ten consecutive patients with moderate to severe portopulmonary hypertension (mean pulmonary artery pressure of 52 [10]mmHg) underwent a 6 minute walk test and a right heart catheterization at baseline and 2 (1) months after β-blocker withdrawal. Results: Following β-blocker withdrawal, 9 of 10 patients increased their 6 minute walked distance with a mean increase in the whole group of 79 (78) meters (P = .01). Cardiac output increased by 28%(P < .01) with no change in mean pulmonary artery pressure, resulting in a 19%decrease in pulmonary vascular resistance (P < .01). Increases in cardiac output were related to a 25%increase in heart rate (P < .01), whereas stroke volume was unchanged (P = .65). The improvements in exercise tolerance were associated with increases in chronotropic response (maximal heart rate minus resting heart rate) from 18 (9) to 34 (12) beats/min (P < .01) during the 6-minute walk test. Conclusions: In patients with moderate to severe portopulmonary hypertension, β-blockers are associated with significant worsening in exercise capacity and pulmonary hemodynamics. These deleterious effects support the contraindication of β-blockers in patients with portopulmonary hypertension. | Provencher S. Herve P. Jais X. 成虹(译) 陈云茹(校) | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，6： | 3 |
| 2 | Biceps tenotomy versus tenodesis: a review of clinical outcomes and biomechanical results显示文摘 | Andrew R. Hsu Neil S. Ghodadra CDR Matthew T. Provencher Paul B. Lewis Bernard R. Bach | 2011 | Journal of Shoulder and Elbow Surgery2011，，2： | 1 |
| 3 | 以波生坦作为一线药物治疗特发性肺动脉高压的远期疗效显示文摘Aims: Data on long-term efficacy of bosentan in unselected idiopathic pulmonary arterial hypertension(IPAH) patients are lacking. We aimed to describe the long-term outcome of consecutive IPAH patients treated first-line with bosentan. Methods and results: A retrospective analysis of 103 consecutive New York Heart Association functional class III/IV IPAH patients treated with bosentan at our centre between November 1999 and May 2004 was performed. The 6-minute walk distance(6MWD) and haemodynamics were assessed at baseline and after 4 and 12 months. Mean follow-up was 24±15 months. At 4 months, significant improvements in exercise capacity and haemodynamics were observed and persisted up to 1 year. Overall survival estimates were 90 and 87%and event-free status(survival without transplantation, prostanoid initiation, or hospitalization for right heart failure) estimates were 61 and 44%at 1 and 2 years, respectively. Forty-five(44%) patients required prostanoid therapy during follow-up. The 6MWD and the right atrial pressure at baseline and the 6MWD, the increase in 6MWD, and the decrease in pulmonary resistance after 4 months of treatment were associated with long-term outcomes. Conclusion: In our series of consecutive IPAH patients treated with bosentan, improvements in exercise capacity and haemodynamics were similar to those observed in previous randomized trials. However, on the basis of local criteria, many patients required the addition of prostanoid therapy during follow-up. | Provencher S. Sitbon O. Humbert M. 苏畅 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，9： | 1 |
| 4 | Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study显示文摘 | Mario Campone Thomas Bachelot Michael Gnant Ines Deleu Hope S. Rugo Barbara Pistilli Shinzaburo Noguchi Mikhail Shtivelband Kathleen I. Pritchard Louise Provencher Howard A. Burris Lowell Hart Bohuslav Melichar Gabriel N. Hortobagyi Francis Arena José Bas | 2013 | European Journal of Cancer2013，，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员